Drug Trial Radar · NCT05125302
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,059
Planned (sponsor's estimate)
Start
Jan 13, 2022
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (aged 6-17 years) with a history of migraine will be enrolled. The study will include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort). Participants aged 6-11 years in the PK Cohort will receive Dose A or Dose B of Ubrogepant for PK analysis to determine dose selection for the main study. In the main study, after dose selection, children aged 6-11 years will be randomized to receive either low or high dose of Ubrogepant or placebo. There is a 1 in 3 chance that a participant will be assigned to placebo. Adolescents aged 12-17 years will be randomized to receive either low or high dose of Ubrogepant or placebo with a 1 in 3 chance of placebo assignment. For qualifying migraine attacks, participants will receive oral tablets of the double-blind study intervention. There will be an option to take a second dose of double-blind study intervention (identical to initial dose), or rescue medication, at least 2 hours after the initial dose, for headache of moderate/severe intensity. Around 1059 participants will be enrolled in the study in approximately 120 sites in the United States. The study duration will be up to 6 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Migraine
Interventions
UbrogepantDrug
Oral Tablet
Placebo-Matching UbrogepantDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 yearsTime frame: 2 hours after initial dose
Locations
129 sites in 2 countries. Site status is shown where the registry gives one.
Rehabilitation & Neurological Services /ID# 229969
Huntsville, Alabama · Recruiting
The Center for Clinical Trials - Saraland /ID# 231546
Saraland, Alabama · Recruiting
Velocity Clinical Research - Phoenix /ID# 274478
Phoenix, Arizona · Recruiting
HealthStar Research Glenwood /ID# 275303
Glenwood, Arkansas · Recruiting
HealthStar Research of Hot Springs /ID# 273256
Hot Springs, Arkansas · Recruiting
Preferred Research Partners /ID# 230725
Little Rock, Arkansas · Recruiting
Advanced Research Center /ID# 227962
Anaheim, California · Recruiting
Neuro Pain Research Center /ID# 227966
Fresno, California · Recruiting
Imax Clinical Trials /ID# 281436
La Palma, California · Recruiting
Alliance for Research Alliance for Wellness /ID# 230546
Long Beach, California · Recruiting
Children's Hospital Los Angeles /ID# 230596
Los Angeles, California · Completed
Paradigm Clinical Research - Modesto, CA /ID# 280611
Modesto, California · Recruiting
Excell Research, Inc /ID# 230899
Oceanside, California · Recruiting
Paradigm Clinical Research - San Diego /ID# 269608
San Diego, California · Recruiting
Lumos Clinical Research Center /ID# 231267
San Jose, California · Recruiting
Pacific Clinical Research Management Group /ID# 231636
Upland, California · Completed
Sunwise Clinical Research /ID# 230971
Walnut Creek, California · Recruiting
Amicis Research Center /ID# 272621
Winnetka, California · Recruiting
Paradigm Clinical Research - Aurora, CO /ID# 280612
Aurora, Colorado · Recruiting
Children's Hospital Colorado - Aurora /ID# 231879
Aurora, Colorado · Recruiting
IMMUNOe Research Centers /ID# 230879
Centennial, Colorado · Completed
MCB Clinical Research Centers - Colorado Springs - South Parkside Drive /ID# 231625
Colorado Springs, Colorado · Completed
New England Institute for Clinical Research /ID# 230635
Stamford, Connecticut · Recruiting
Emerson Clinical Research Institute - Connecticut Avenue - Washington /ID# 231693
Washington D.C., District of Columbia · Recruiting
Encore Medical Research of Boynton Beach LLC /ID# 246833
Boynton Beach, Florida · Recruiting
Gulf Coast Clinical Research Center /ID# 230020
Fort Myers, Florida · Recruiting
Sarkis Clinical Trials /ID# 227956
Gainesville, Florida · Completed
Northwest Florida Clinical Research Group, LLC /ID# 231069
Gulf Breeze, Florida · Completed
AGA Clinical Trials /ID# 230554
Hialeah, Florida · Recruiting
Encore Medical Research /ID# 245682
Hollywood, Florida · Recruiting
Advanced Research Institute of Miami /ID# 230292
Homestead, Florida · Completed
Auzmer Research /ID# 239251
Lakeland, Florida · Completed
Columbus Clinical Services, Llc /Id# 230880
Miami, Florida · Recruiting
My Preferred Research LLC /ID# 227886
Miami, Florida · Recruiting
Neurology & Pain Medicine /ID# 240168
Miami, Florida · Completed
Medical Research Group of Central Florida /ID# 231632
Orange City, Florida · Recruiting
Clinical Associates of Orlando, LLC /ID# 272619
Orlando, Florida · Recruiting
Suncoast Clinical Research - Palm Harbor /ID# 229337
Palm Harbor, Florida · Completed
FWD Clinical Research - Spring Hill /ID# 229815
Spring Hill, Florida · Recruiting
University of South Florida- Neuroscience Institute /ID# 229324
Tampa, Florida · Recruiting
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.